 |
N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide |
|---|---|
| Trade Name | |
| Orphan Indication | Non-small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2017-09-05 00:00:00 |
| Sponsor | Checkpoint Therapeutics, Inc.;2 Gansevoort Street, 9th Floor;New York, New York, 10014 |
Related Access Program